Rituximab maintenance improves overall survival of patients with follicular lymphoma—Individual patient data meta-analysis-Reference-Cited by-同舟云学术

Rituximab maintenance improves overall survival of patients with follicular lymphoma—Individual patient data meta-analysis

Published:2017-05 Issue: Volume:76 Page:216-225
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Vidal Liat,Gafter-Gvili Anat,Salles Gilles,Bousseta Sami,Oberman Bernice,Rubin Carmit,van Oers Marinus H.J.,Fortpied Catherine,Ghielmini Michele,Pettengell Ruth,Witzens-Harig Mathias,Dreger Peter,Vitolo Umberto,Gomes da Silva Maria,Evangelista Andrea,Li Hailun,Freedman Laurence,Habermann Thomas M.,Shpilberg Ofer

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference19 articles.

1. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials;Vidal;J Natl Cancer Inst,2011

2. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. [Internet];Ardeshna;Lancet Oncol,2014

3. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)

4. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. [Internet];Ghielmini;Blood,2004

5. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma – a randomized phase II trial of the Minnie Pearl Cancer Research Network. [Internet];Hainsworth;J Clin Oncol,2005

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current Trends and Innovative Approaches in Cancer Immunotherapy;AAPS PharmSciTech;2024-07-24

2. Mortality in patients with lymphoid malignancies and multiple myeloma was stable upon and during the COVID‐19 pandemic: A population‐based, nation‐wide study;HemaSphere;2024-03

3. A Review of Anti-CD20 Antibodies in the Management of B-Cell Lymphomas;Lymphatics;2024-01-05

4. Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma;Manual of Hematopoietic Cell Transplantation and Cellular Therapies;2024

5. Treatment of relapsed follicular lymphoma;Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal;2024